Table of Contents
Executive summary
- Generics growth drivers and resistors
- Consolidation within the generics industry
- The generics industry by country and region
- Therapy area analysis
- Leading generics pharma companies
Chapter 1 - Generics growth drivers and resistors
- Growth drivers for generics
- Company growth opportunities
- Growth through paragraph IV challenges
- Generic biologics
- Mergers and acquisitions
- External factors influencing generics growth
- Healthcare cost containment
- Improving drug approval pathways
- Improving the biosimilars approval pathway
- Threats to the generics industry
- Patent litigation
- Reformulation
- DTC and Rx to OTC switching
- Authorized generics and in-house generics
Chapter 2 - Consolidation within the generics industry
- M&A strategies
- Manufacturing facilities
- Economies of scale
- Generic biologics
- Therapeutic expansion
- Drug technology access
- Geographic expansion and diversification
- Selected M&A deals
- Actavis
- Acquisition of Alpharma
- Acquisition of Amide
- Acquisition of Sindan
- Acquisition of Keri Pharma
- Apotex
- Acquisition of Lareq
- Acquisition of Topgen
- Daiichi Sankyo
- Dr. Reddy' s
- Acquisition of Betapharm
- Acquisition of Roche' s API facility
- Acquisition of Trigenesys
- Hospira
- Acquisition of Mayne Pharma
- Mylan
- Acquisition of Matrix Laboratories
- Acquisition of Merck KGaA' s generics business
- Novartis (Sandoz)
- Acquisition of Sabex
- Acquisition of Hexal and Eon
- Ratiopharm
- Acquisition of Magnafarma
- Acquisition of Pulmotec and Ribosepharm
- Sanofi-Aventis (Winthrop)
- Acquisition of Zentiva
- Acquisition of Laboratorios Kendrick
- Stada
- Acquisition of Hemofarm
- Acquisition of Nizopharm
- Other acquisitions
- Teva
- Acquisition of Barr
- Acquisition of Ivax
- Watson
- Acquisition of Arrow
- Acquisition of Amarin
- Acquisition of Sekhsaria
- Acquisition of Andrx
Chapter 3 - The generics industry by country and region
- Summary
- Introduction
- North America
- Five major European markets
- Central and Eastern Europe
- AsiaPac
- Japan
- China
- Other selected AsiaPac markets
Chapter 4 - Therapeutic analysis of the generics industry
- CNS market
- Leading generics companies by sales
- Top selling molecules
- Cardiovascular market
- Leading generics companies by sales
- Top selling molecules
- Anti-infectives market
- Leading generics companies by sales
- Top selling molecules
- Alimentary tract and metabolism market
- Leading generics companies by sales
- Top selling molecules
- Oncology market
- Leading generics companies by sales
- Top selling molecules
Chapter 5 - Leading generics companies
- Sales analysis of key generics players
- Unbranded generics sales
- Branded and unbranded focus
- Regional analysis of leading generics players
- Company portfolio and strategic analysis
- Teva
- Mylan
- Novartis (Sandoz)
- Ratiopharm
- Watson
- Stada
- Hospira
- Apotex
- Servier
- Pfizer (Greenstone)
- Future Outlook
- Cost containment
- Outperforming branded pharmaceuticals
- Biogenerics/Biosimilars
- Loss of price advantage and low cost manufacturers
Chapter 6 - Appendix
- Primary research methodology
- Glossary
- Index
List of Figures
- Figure 1.1: Growth opportunities and threats for generics companies
- Figure 1.2: Average number per month of original and total ANDA approvals
by the FDA, 2001-2009
- Figure 1.3: A typical timeline for a non-paragraph IV and paragraph IV
ANDA submission
- Figure 1.4: Number of ANDA approvals, 1999 - 2009
- Figure 2.5: Key M&A deals by region
- Figure 2.6: M&A drivers and resistors by region
- Figure 3.7: Unbranded sales and annual growth by country, 2007-08
- Figure 4.8: Therapy area market shares, 2004 & 2008
- Figure 5.9: Contribution of unbranded sales to total sales of top ten
generics companies
List of Tables
- Table 2.1: Key M&A deals by region and strategy
- Table 3.2: Selected country performance of the unbranded generics market,
2004-08
- Table 3.3: Unbranded sales performance in North America, 2007-08
- Table 3.4: Unbranded sales performance of the five major markets in
Europe, 2007-08
- Table 3.5: Unbranded sales performance of the key Eastern European
markets, 2007-08
- Table 3.6: Unbranded sales performance of the major Asian and Pacific
markets, 2007-08
- Table 3.7: Unbranded sales performance of the major Latin American
markets, 2007-08
- Table 4.8: 7MM unbranded sales for major therapy areas, 2008
- Table 4.9: Top five generics companies by CNS sales, 2008
- Table 4.10: Sales of the top five CNS molecules, 2008
- Table 4.11: Top five generics companies by cardiovascular sales, 2008
- Table 4.12: Sales of the top five cardiovascular molecules, 2008
- Table 4.13: Top five generics companies by anti-infectives sales, 2008
- Table 4.14: Sales of the top five anti-infective molecules, 2008
- Table 4.15: Top five generics companies by alimentary tract & metabolism
sales, 2008
- Table 4.16: Sales of the top five alimentary tract & metabolism molecules,
2008
- Table 4.17: Top five generics companies by oncology sales, 2008
- Table 4.18: Sales of the top five oncology molecules, 2008
- Table 5.19: Leading generic pharmaceutical companies by 7MM, unbranded
generic sales, 2007-08
- Table 5.20: Leading generics companies by geography and generic sales, 2008
- Table 5.21: Five leading generic products for Teva, 2007-08
- Table 5.22: Five leading generic products for Mylan, 2007-08
- Table 5.23: Five leading generic products for Novartis, 2007-08
- Table 5.24: Five leading generic products for Ratiopharm, 2007-08
- Table 5.25: Five leading generic products for Watson, 2007-08
- Table 5.26: Five leading generic products for Stada, 2007-08
|
Related Report
|
View Cart
